GSA CAPITAL PARTNERS LLP

Position in PHAT — Phathom Pharmaceuticals, Inc.

CIK 1362033 LONDON, X0

Position in PHAT

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$1,078,425

-$292,307 QoQ

Shares Held

97,068

+17.5% QoQ

Ownership

0.122%

of shares outstanding

% of Portfolio

0.08%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2020

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $100,711,343 across 163 Biotechnology names. PHAT ranks #34 (1.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc.	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,078,425	97,068	+17.5%	Shares	Sole	2026-05-08
2025-12-31	$1,370,732	82,624	+17.6%	Shares	Sole	2026-02-06
2025-09-30	$826,936	70,258	+363.0%	Shares	Sole	2025-11-07
2024-12-31	$123,204	15,173	+0.6%	Shares	Sole	2025-02-07
2024-09-30	$272,700	15,083	-48.7%	Shares	Sole	2024-11-05
2024-06-30	$302,881	29,406	+107.5%	Shares	Sole	2024-08-15
2024-03-31	$150,527	14,174	-88.4%	Shares	Sole	2024-05-03
2023-09-30	$1,264,020	121,892	+126.1%	Shares	Sole	2023-11-15
2023-06-30	$771,976	53,909	+166.5%	Shares	Sole	2023-08-14
2023-03-31	$144,456	20,232	+9.3%	Shares	Sole	2023-05-12
2022-12-31	$207,760	18,517	-15.3%	Shares	Sole	2023-02-13
2020-12-31	$726,554	21,871	—	Shares	Sole	2021-02-03
No filing history on record for this holder in this stock.